08:00 Fri 03 Apr 2020
ReNeuron Group plc - COVID-19 Update
|
AIM: RENE |
ReNeuron Group plc
("
COVID-19 update
The safety of employees, suppliers, clinical trial participants and all other people with whom the Company interacts is of over-riding importance to the Company. The Company is complying with governmental advice and requirements across its operations in the
The Company's priority internal research projects are continuing to progress to current timelines. Consumables and reagents are still widely available and the Company's own consumable inventories are such that all current internal research activities can continue without being significantly impacted.
Following the outbreak of the COVID-19 pandemic, the Company has initiated a research programme focused on the potential utility of its proprietary exosomes as a delivery vehicle for viral vaccines. Previously presented, unpublished data show that
Government measures to contain the spread of the coronavirus are having an increasing effect on most clinical studies, including in the US, where the Company is running two clinical trials with its therapeutic candidates for stroke disability and retinitis pigmentosa. As a consequence, these clinical studies will be subject to some delays in patient recruitment and the Company will provide further guidance regarding the timing of availability of top-line data from the studies in due course. Patients already treated continue to be followed up in both studies, on a remote basis where this is necessary in order to ensure patient safety.
The Company will continue to monitor the impact of COVID-19 on its business, taking further action where necessary and announcing further updates as appropriate.
ENDS
Contacts:
ReNeuron |
+44 (0) 20 3819 8400 |
Olav Hellebø, Chief Executive Officer |
|
Michael Hunt, Chief Financial Officer |
|
Buchanan (UK Media/Investor Relations) |
+44 (0) 20 7466 5000 |
Mark Court, Tilly Abraham |
|
Claudia Styslinger, David Rosen |
+1 212 600 1902 |
|
|
Jonathan Senior, Stewart Wallace, Ben Maddison |
+44 (0) 20 7710 7600
|
N+1 Singer (Joint Broker) Aubrey Powell, James Moat, Tom Salvesen |
+44 (0) 20 7496 3000 |
|
|
About ReNeuron
ReNeuron is a global leader in cell-based therapeutics, harnessing its unique stem cell technologies to develop 'off the shelf' stem cell treatments, without the need for immunosuppressive drugs. The Company's lead clinical-stage candidates are in development for the blindness-causing disease, retinitis pigmentosa, and for disability as a result of stroke. ReNeuron is also advancing its proprietary exosome technology platform as a potential delivery system for drugs that would otherwise be unable to reach their site of action. ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. For further information visit www.reneuron.com.
This information is provided by RNS, the news service of the
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of...
FOR OUR FULL DISCLAIMER CLICK HERE